Navigation Links
Synta Oncology Candidate STA-4783 Clinical Trial Results to Be,Presented at the ASCO Annual Meeting

LEXINGTON, Mass.--(BUSINESS WIRE)--May 23, 2007 - Synta Pharmaceuticals Corp., (NASDAQ: SNTA) a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that survival and sub-population data from the Phase 2b clinical trial in metastatic melanoma of the Company's lead oncology drug candidate, STA-4783, will be presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois on Tuesday, June 5, 2007. In this double-blind, randomized, multi-center trial, patients treated with STA-4783 in combination with paclitaxel were compared with patients treated with paclitaxel alone. All patients had stage IV metastatic melanoma.

STA-4783 is a novel, injectable, small molecule investigational drug candidate that induces a potent oxidative stress response in cancer cells, driving programmed cell death and enhancing the activity of anti-cancer agents that act through the mitochondrial apoptosis pathway, including paclitaxel. In September 2006, Synta reported positive Phase 2b results for STA-4783 in combination with paclitaxel in a double-blind, randomized, controlled, multi-center clinical trial in patients with stage IV metastatic melanoma. In November 2006, Synta received Fast Track designation from the FDA for the development of STA-4783 in metastatic melanoma. Synta plans to initiate a pivotal Phase 3 clinical trial for STA-4783 in mid-2007 and one or more Phase 2 studies in other cancer indications later in the year.

The schedule and meeting places for the presentation, together with the abstract numbers, are listed below:

Poster Presentations

Tuesday, June 5, 2007 at 8:00 a.m. to 12:00 p.m. - Poster Presentation: 17

Abstract No. 8528

"Subgroup analysis of efficacy and safety analysis of a randomized, double-blinded controlled phase 2 study of STA-47
'"/>




Page: 1 2 3

Related medicine technology :

1. Synta Presents Results for STA-4783 in Metastatic Melanoma Showing Improvement in Overall Survival
2. Synta Pharmaceuticals to Host Conference Call Today
3. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
4. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
5. Gloucester Pharmaceuticals Reports Positive Interim Phase II Data on Romidepsin for T-Cell Lymphomas at the 2007 American Society of Clinical Oncology Annual Meeting
6. MGI Pharma Summarizes Data Presented at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting
7. MGI Pharma, Inc. Summarizes Data Presented at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting
8. Hana Biosciences Presents Data On Two Programs At the American Society of Clinical Oncology Annual Meeting
9. Access and Somanta Announce Data to be Presented on Angiolix at ASCO Oncology Conference
10. Pharmion to Present Clinical Data on Commercial and Pipeline Products at 2007 American Society of Clinical Oncology (ASCO) Meeting
11. CytImmune Presents Positive CYT-6019 Data During the American Society of Clinical Oncology Annual Meeting in Chicago
Post Your Comments:
(Date:1/15/2014)... 15, 2014 MultiCell Technologies, Inc. (OTC Bulletin Board: ... patent application concerning composition of matter, biological targets, mechanism ... cell death.  This patent application describes ... RNA molecules (VSRNAs) which interfere with the basic homeostatic ...
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... & Forecast – Worldwide Analysis ... Pump Market Analysis ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... market research report is available in ... Global Markets and Technologies for Advanced ... Routes of Administration ...
Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16
... 31, 2011 Ambry Genetics today introduces their ...  The Ambry CancerArray™ is a high resolution exon-focused ... probe density coverage in over 400 known cancer-associated ... functionally important cancer regions. (Logo:   ...
... 31, 2011 CANTEL MEDICAL CORP. (NYSE: ... & CEO, will be presenting at the CL King 9th ... 11:15 AM EDT on Tuesday, September 13, 2011 at the ... Q & A session immediately following the presentation. In addition, ...
Cached Medicine Technology:Ambry Genetics Announces Launch of Their CancerArrayâ„¢ Product and Services Utilizing aCGH Technology 2
(Date:7/9/2014)... in policing injection drug users in Russia might ... , A study, conducted by researchers from Boston ... collaboration with St. Petersburg Pavlov State University, sought ... the health outcomes of a cohort of HIV-positive ... Those who were arrested by police were more ...
(Date:7/9/2014)... By looking at ... structure and function, personality, life experiences and genetics, researchers can ... binge drinking within the next two years. Impulsivity, hopelessness, sensation-seeking ... events and a family history of drug use contribute to ... child had had a single drink at age 14 was ...
(Date:7/9/2014)... the world have been linked to an emerging ... the National Institute for Mathematical and Biological Synthesis ... contribute. , In a series of mathematical ... hemorrhage of internal organs in frogs, could cause ... they are exposed to the virus every few ...
(Date:7/9/2014)... of Allergy and Infectious Diseases (NIAID), part of ... early-stage clinical trial of CRS3123, an investigational oral ... ( C. difficile ) infection. CRS3123 (previously known ... C. difficile growth while sparing normal intestinal bacteria. ... to 30 healthy men and women ages 18 ...
(Date:7/9/2014)... printing on prescription labels handed out by pharmacists ... in taking medication, according to new research by ... Institute for the Blind)., The study, published recently ... that labels on prescription medications dispensed by pharmacies ... legibility. , By simply following recommended guidelines for ...
Breaking Medicine News(10 mins):Health News:BU researchers relate arrests with HIV risk environment 2Health News:What drives a child to abuse alcohol? 2Health News:Study predicts ranavirus as potential new culprit in amphibian extinctions 2Health News:NIH launches Phase I clinical trial of novel drug to treat Clostridium difficile infection 2Health News:Most prescription labels fail to meet guidelines, risking dosage errors 2
... is widespread among U.S. adolescents and young adults ages 14 ... the University at Buffalos Research Institute on Addictions (RIA). ... the first national survey of its kind show problem gambling ... (for example, gambling more than you intended or stealing money ...
... Vascular Insights LLC announced,today that it has received ... (FDA) to market its ClariVein(TM) infusion catheter for,infusion ... ClariVein(TM) is a percutaneous, 2 2/3 Fr (0.035") ... that enhances fluid dispersion in the,treatment area., ...
... 6 Epitomics, Inc. announced,today that its Hangzhou ... and production of its novel line of rabbit ... standard for quality management and ultimately the finest ... Dr. Guo-Liang Yu,President and CEO of Epitomics, Inc., ...
... Care Management: Making a ... Difference Today and Tomorrow, HARRISBURG, ... Medical Officer, will deliver the clinical keynote,address on Wednesday afternoon, ... the World of Care Management. Dr. Petrulis will,present Care Management: ...
... at dilated veins seen with cirrohosis but aren,t sensitive ... New noninvasive methods to detect esophageal bleeding in people ... Italian and American researchers. , About 25 percent of ... are extremely dilated veins commonly seen with cirrhosis. Variceal ...
... bowel movement, serious complications can follow, experts note , , ... have identified a marker that might predict which pregnant ... is essentially a baby,s first bowel movement, excreted in ... It is considered a sign of fetal distress. A ...
Cached Medicine News:Health News:Estimated 750,000 problem gamblers among America's youth 2Health News:Estimated 750,000 problem gamblers among America's youth 3Health News:Epitomics receives ISO 9001 certification for the production of Rabbit Monoclonal Antibodies. 2Health News:KePRO's Chief Medical Officer to Deliver Clinical Keynote Address 2Health News:Noninvasive Procedures Show Promise for Esophageal Bleeding 2Health News:Doctors Discover Marker for Meconium Passage During Delivery 2
... of healthcare associated infections can be prevented with ... action a healthcare worker can do to reduce ... Alcohol gel hand sanitization is fast, easy to ... with soap and water. , Aplicare's 62% Ethyl ...
This is long known for its purity and mildness, Castile Soap is also an effective cleaning agent that is used in a variety of applications. It rinses clean while leaving the skin soft and healthy....
... not leave your hands dry, cracked or ... Antimicrobial action, CHG Skin Cleanser attacks a ... gram-positive bacteria, fungi, and yeasts. It is ... wash. The solution does not contain red ...
BD Persist Plus protective barrier skin preps with chlorhexidine in alcohol...
Medicine Products: